← Leaderboards

Robert L Ferris

University Of Pittsburgh At Pittsburgh

Google Scholar ↗PubMed ↗ORCID ↗

$24,076,317

Attributed

$28,679,139

Total exposure

23

Grants

21

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $11.8M · FY2005–25

$20M$15M$10M$5M$0

'05

'06

'07

'08

'09

'10

'11

'12

'13

'14

'15

'16

'17

'18

'19

'20

'21

'22

'23

'24

'25

Funding mix

By agency

NIH$105,913,128 · 26

By mechanism

P30$69,529,144 · 13

P50$24,072,381 · 6

R01$11,564,887 · 5

T32$735,057 · 1

M01$11,659 · 1

Top collaborators

Most similar at University Of Pittsburgh At Pittsburgh

Same institution · by research overlap

Arthur S Levine$16,970,938
Mack T Ruffin$5,808,265
Mingui Sun$11,879,919
Richard R Guido$0
Simon C Watkins$30,927,669

Others in their field

Top investigators on “Programs”

David Heimbrook · Leidos Biomedical Research, Inc.$1,641,009,751
Leonard Freedman · Leidos Biomedical Research, Inc.$994,984,644
Lawrence Corey · Fred Hutchinson Cancer Center$730,186,538
Sonia M Thomas · Research Triangle Institute$700,865,642
David Divins · Consortium For Ocean Leadership, Inc$609,772,544
Larry Arthur$609,313,548

Research focus

ProgramsFundingTranslational ResearchMalignant NeoplasmsResearch PersonnelUniversitiesTumorCollaborationsCancer Center Support GrantMemberEnsureBasic ScienceHead And Neck CancerLeadershipClinical ResearchBaseMissionResource SharingAnticancer ResearchFacultyCancer PatientClinical TrialsAreaInstitution

Grant awards (114)

Cancer Center Support Grant$8,402,447

P30 · FY2025 · CA · contact PI

Identifying cellular and molecular signatures from distinct T cell receptor clonotypes associated with favorable immune checkpoint inhibitor responses in HNSCCs$762,411

R01 · FY2025 · DE · contact PI

Mechanistic connection between HPV-specific TCRs and therapeutic responses to ICI in HPV+ HNSCC$655,244

R01 · FY2025 · CA

Planning and Evaluation$589,515

P30 · FY2025 · CA · contact PI

Mechanisms of PD-1 and Tim-3 crosstalk in tumor-infiltrating lymphocytes$541,414

R01 · FY2025 · CA

Cancer Center Support Grant$357,575

P30 · FY2025 · CA · contact PI

Head and Neck Cancer SPORE$2,030,091

P50 · FY2024 · CA · contact PI

Leadership, Planning and Evaluation$1,007,573

P30 · FY2024 · CA · contact PI

Developmental Funds$776,186

P30 · FY2024 · CA · contact PI

Identifying cellular and molecular signatures from distinct T cell receptor clonotypes associated with favorable immune checkpoint inhibitor responses in HNSCCs$747,163

R01 · FY2024 · DE · contact PI

Mechanistic connection between HPV-specific TCRs and therapeutic responses to ICI in HPV+ HNSCC$655,244

R01 · FY2024 · CA

Mechanisms of PD-1 and Tim-3 crosstalk in tumor-infiltrating lymphocytes$514,343

R01 · FY2024 · CA

Core A: Administrative Core$431,581

P50 · FY2024 · CA · contact PI

Optimization of anti-LANA CD8+ as an therapeutic immunogen (Immune/Microenvironment)$250,000

P30 · FY2024 · CA · contact PI

Cancer Center Administration$212,796

P30 · FY2024 · CA · contact PI

Exploration of Contemporary Modifiable Exposures and Cancer in Beauty Salons$100,000

P30 · FY2024 · CA · contact PI

Cancer Center Support Grant$5,995,559

P30 · FY2023 · CA · contact PI

Head and Neck Cancer SPORE$2,112,973

P50 · FY2023 · CA · contact PI

Leadership, Planning and Evaluation$1,007,573

P30 · FY2023 · CA · contact PI

Developmental Funds$776,186

P30 · FY2023 · CA · contact PI

Identifying cellular and molecular signatures from distinct T cell receptor clonotypes associated with favorable immune checkpoint inhibitor responses in HNSCCs$681,410

R01 · FY2023 · DE · contact PI

Mechanisms of PD-1 and Tim-3 crosstalk in tumor-infiltrating lymphocytes$541,414

R01 · FY2023 · CA

Core A: Administrative Core$446,778

P50 · FY2023 · CA · contact PI

Cancer Center Administration$212,796

P30 · FY2023 · CA · contact PI

Cancer Center Support Grant$5,995,559

P30 · FY2022 · CA · contact PI

Head and Neck Cancer SPORE$2,138,140

P50 · FY2022 · CA · contact PI

Leadership, Planning and Evaluation$1,007,573

P30 · FY2022 · CA · contact PI

Developmental Funds$776,186

P30 · FY2022 · CA · contact PI

Identifying cellular and molecular signatures from distinct T cell receptor clonotypes associated with favorable immune checkpoint inhibitor responses in HNSCCs$678,731

R01 · FY2022 · DE · contact PI

Core A: Administrative Core$447,201

P50 · FY2022 · CA · contact PI

Cancer Center Administration$212,796

P30 · FY2022 · CA · contact PI

Cancer Center Support Grant Supplement: âAsking and Tellingâ: Education and Process around the Implementation of SOGI assessment within the UPMC Hillman Cancer Center network.$150,000

P30 · FY2022 · CA · contact PI

Cancer Center Support Grant$5,909,145

P30 · FY2021 · CA · contact PI

Leadership, Planning and Evaluation$894,008

P30 · FY2021 · CA · contact PI

Developmental Funds$688,702

P30 · FY2021 · CA · contact PI

Cancer Center Administration$188,813

P30 · FY2021 · CA · contact PI

Cancer Center Support Grant$124,617

P30 · FY2021 · CA · contact PI

Cancer Center Support Grant$5,901,161

P30 · FY2020 · CA · contact PI

Cancer Center Support Grant Supplement: Clinical Evaluation of a Q GRFT Nasal Spray for Prevention of SARS-CoV-2$1,197,257

P30 · FY2020 · CA · contact PI

Leadership, Planning and Evaluation$991,731

P30 · FY2020 · CA · contact PI

Developmental Funds$763,983

P30 · FY2020 · CA · contact PI

Mechanisms of PD-1 and Tim-3 crosstalk in tumor-infiltrating lymphocytes$499,975

R01 · FY2020 · CA · contact PI

Cancer Center Administration$209,449

P30 · FY2020 · CA · contact PI

Cancer Center Support Grant$200,000

P30 · FY2020 · CA · contact PI

Cancer Center Support Grant$200,000

P30 · FY2020 · CA · contact PI

Cancer Center Support Grant$122,954

P30 · FY2020 · CA · contact PI

Cancer Center Support Grant$60,000

P30 · FY2020 · CA · contact PI

Cancer Center Support Grant$5,129,654

P30 · FY2019 · CA · contact PI

Head and Neck Cancer SPORE$2,127,841

P50 · FY2019 · CA · contact PI

ADMINISTRATION (Admin Core)$761,202

P30 · FY2019 · CA · contact PI

DEVELOPMENTAL FUNDS (Core 002)$538,114

P30 · FY2019 · CA · contact PI

Mechanisms of PD-1 and Tim-3 crosstalk in tumor-infiltrating lymphocytes$484,976

R01 · FY2019 · CA · contact PI

Cancer Center Support Grant$249,564

P30 · FY2019 · CA · contact PI

Administrative Core$144,078

P50 · FY2019 · CA · contact PI

Checkpoint Receptor Targeting to Enhance Cetuximab Efficacy Against HNSCC$136,751

P50 · FY2019 · CA · contact PI

PLANNING AND EVALUATION (Core 001)$132,652

P30 · FY2019 · CA · contact PI

Cancer Center Support Grant$60,000

P30 · FY2019 · CA · contact PI

Cancer Center Support Grant$5,129,654

P30 · FY2018 · CA · contact PI

Head and Neck Cancer SPORE$2,300,000

P50 · FY2018 · CA · contact PI

Mechanisms of PD-1 and Tim-3 crosstalk in tumor-infiltrating lymphocytes$499,177

R01 · FY2018 · CA · contact PI

Administrative Core$462,688

P50 · FY2018 · CA · contact PI

Cancer Center Support Grant$249,783

P30 · FY2018 · CA · contact PI

Postdoctoral Research Training in Head and Neck Oncology$152,006

T32 · FY2018 · CA · contact PI

Checkpoint Receptor Targeting to Enhance Cetuximab Efficacy Against HNSCC$119,737

P50 · FY2018 · CA · contact PI

Cancer Center Support Grant$115,192

P30 · FY2018 · CA · contact PI

Cancer Immunology Program (Project-003)$34,500

P30 · FY2018 · CA · contact PI

Cancer Immunology Program (Project-003)$8,614

P30 · FY2018 · CA · contact PI

Cancer Immunology Program (Project-003)$3,972

P30 · FY2018 · CA · contact PI

Cancer Center Support Grant$5,129,654

P30 · FY2017 · CA · contact PI

Head and Neck Cancer SPORE$2,293,901

P50 · FY2017 · CA · contact PI

Mechanisms of PD-1 and Tim-3 crosstalk in tumor-infiltrating lymphocytes$495,583

R01 · FY2017 · CA · contact PI

Cancer Center Support Grant$175,000

P30 · FY2017 · CA · contact PI

Administrative Core$152,520

P50 · FY2017 · CA · contact PI

Checkpoint Receptor Targeting to Enhance Cetuximab Efficacy Against HNSCC$144,455

P50 · FY2017 · CA · contact PI

Cancer Center Support Grant$115,192

P30 · FY2017 · CA · contact PI

Postdoctoral Research Training in Head and Neck Oncology$75,534

T32 · FY2017 · CA · contact PI

Cancer Center Support Grant$55,932

P30 · FY2017 · CA · contact PI

Cancer Immunology Program (Project-003)$34,500

P30 · FY2017 · CA · contact PI

Cancer Center Support Grant$5,129,654

P30 · FY2016 · CA · contact PI

Head and Neck Cancer SPORE$2,260,252

P50 · FY2016 · CA · contact PI

Cancer Center Support Grant$749,690

P30 · FY2016 · CA · contact PI

Mechanisms of PD-1 and Tim-3 crosstalk in tumor-infiltrating lymphocytes$491,988

R01 · FY2016 · CA · contact PI

Cancer Center Support Grant$199,837

P30 · FY2016 · CA · contact PI

Administrative Core$161,133

P50 · FY2016 · CA · contact PI

Checkpoint Receptor Targeting to Enhance Cetuximab Efficacy Against HNSCC$153,917

P50 · FY2016 · CA · contact PI

Cancer Center Support Grant$115,192

P30 · FY2016 · CA · contact PI

Postdoctoral Research Training in Head and Neck Oncology$111,649

T32 · FY2016 · CA · contact PI

Cancer Center Support Grant$60,000

P30 · FY2016 · CA · contact PI

Cancer Immunology Program (Project-003)$34,673

P30 · FY2016 · CA · contact PI

Head and Neck Cancer SPORE$2,185,000

P50 · FY2015 · CA · contact PI

Checkpoint Receptor Targeting to Enhance Cetuximab Efficacy Against HNSCC$292,567

P50 · FY2015 · CA · contact PI

Administrative Core$290,969

P50 · FY2015 · CA · contact PI

Postdoctoral Research Training in Head and Neck Oncology$122,611

T32 · FY2015 · CA · contact PI

Cancer Immunology Program (Project-003)$34,779

P30 · FY2015 · CA · contact PI

Specialized Program of Research Excellence$2,155,519

P50 · FY2014 · CA · contact PI

Immune activation by cetuximab in head and neck cancer patients$374,963

R01 · FY2014 · DE · contact PI

Cellular Immunity and Immune Escape from EGFR Antibody Therapy$178,980

P50 · FY2014 · CA · contact PI

Postdoctoral Research Training In Head And Neck Oncology$137,731

T32 · FY2014 · CA · contact PI

Immune activation by cetuximab in head and neck cancer patients$359,964

R01 · FY2013 · DE · contact PI

Cellular Immunity and Immune Escape from EGFR Antibody Therapy$285,063

P50 · FY2013 · CA · contact PI

Immune activation by cetuximab in head and neck cancer patients$178,136

R01 · FY2013 · DE · contact PI

Postdoctoral Research Training In Head And Neck Oncology$135,526

T32 · FY2013 · CA · contact PI

Immune activation by cetuximab in head and neck cancer patients$374,963

R01 · FY2012 · DE · contact PI

Cellular Immunity and Immune Escape from EGFR Antibody Therapy$195,220

P50 · FY2012 · CA · contact PI

Immune activation by cetuximab in head and neck cancer patients$367,388

R01 · FY2011 · DE · contact PI

Cellular Immunity and Immune Escape from EGFR Antibody Therapy$200,210

P50 · FY2011 · CA · contact PI

Immune activation by cetuximab in head and neck cancer patients$378,750

R01 · FY2010 · DE · contact PI

Chemokine Signals in Head and Neck Cancer Progression$254,739

R01 · FY2010 · CA · contact PI

Cellular Immunity and Immune Escape from EGFR Antibody Therapy$224,816

P50 · FY2010 · CA · contact PI

Chemokine Signals in Head and Neck Cancer Progression$254,774

R01 · FY2009 · CA · contact PI

Chemokine Signals in Head and Neck Cancer Progression$254,809

R01 · FY2008 · CA · contact PI

Chemokine Signals in Head and Neck Cancer Progression$254,842

R01 · FY2007 · CA · contact PI

Chemokine Signals in Head and Neck Cancer Progression$262,486

R01 · FY2006 · CA · contact PI

DIRECT MEASUREMENT RATES SYNTHESIS TURNOVER T-LYMPHOCYTES HEAD/NECK CANCER$11,659

M01 · FY2005 · RR